Young Therapeutics LLC
Philadelphia, PA Doing business as Young Therapeutics LLC
- UEI
- JY3KKMRM47L6
- CAGE
- 855J9
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1715 Stanwood St, Philadelphia, PA 19152, USA
- Website
- youngtherapeutics.com
- Industry
-
- Information Technology
- Software & Services
- Internet Software & Services
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Minimizing myocardial damage and loss of cardiac function post myocardial infarction using targeted PKC inhibitors 002… | National Heart Lung and Blood Institute | $4,466,697 | |
| Young, lindon h - project summary we are seeking funding to test the cardio protective effects of a novel new protein… | National Heart Lung and Blood Institute | $1,680,783 | |
| The effects of protein kinase c epsilon peptide inhibitor (YT-001) in warm murine kidney ischemia-reperfusion | National Institute of Diabetes and Digestive and Kidney Diseases | $351,000 |
About Young Therapeutics LLC
Young Therapeutics LLC is a for-profit limited liability company based in Philadelphia, Pennsylvania, registered in the System for Award Management (SAM) since July 2018. The company appears to be focused on pharmaceutical research and development, specifically targeting innovative therapeutic compounds for cardiovascular and renal disease treatment. While detailed information about the company's full operational scope is not provided, their federal grant awards suggest they are a research-driven organization specializing in developing targeted protein kinase inhibitors with potential medical applications.
The company has been awarded multiple federal grants from prestigious institutes like the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases, primarily focused on developing novel protein kinase inhibitors for addressing ischemia-reperfusion injury. Their most recent significant grant (R44HL160338) is a $1,488,899 project grant aimed at developing and validating two proprietary compounds, YT-002 and YT-004, which target specific protein kinases to preserve myocardial tissue and function following heart attacks. Previous grants include research on compounds like YT-001 for exploring cardioprotective and renal protective effects, with studies conducted in rat and porcine models. The research involves sophisticated scientific approaches such as pharmacokinetic and pharmacodynamic studies, with the ultimate goal of transitioning these compounds into potential clinical trials and developing groundbreaking treatments for cardiovascular and kidney diseases.
Quick answers
What is Young Therapeutics LLC's UEI?
Young Therapeutics LLC's Unique Entity ID (UEI) in SAM.gov is JY3KKMRM47L6.
What is Young Therapeutics LLC's CAGE code?
Young Therapeutics LLC's CAGE code is 855J9.
What is Young Therapeutics LLC's primary NAICS code?
Young Therapeutics LLC's primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Young Therapeutics LLC located?
Young Therapeutics LLC's physical address in SAM.gov is 1715 Stanwood St, Philadelphia, PA 19152, USA.
Is Young Therapeutics LLC registered in SAM.gov?
Yes. Young Therapeutics LLC's SAM.gov registration is active through March 12, 2027.
What is Young Therapeutics LLC's most recent federal award?
Young Therapeutics LLC's most recent federal grant award is Minimizing myocardial damage and loss of cardiac function post myocardial infarction using targeted PKC inhibitors 002… (R44HL160338), from National Heart Lung and Blood Institute, on April 1, 2025.
On GovTribe
See Young Therapeutics LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors